Albany Molecular Research (AMRI) 22.20 $AMRI
Albany Molecular Research posts 2Q profit
Automated Insights - Tue Aug 04, 7:42AM CDT
ALBANY, N.Y. (AP) _ Albany Molecular Research Inc. (AMRI) on Tuesday reported second-quarter profit of $2.3 million.
AMRI: 22.20 (+0.19)
AMRI Announces Second Quarter 2015 Results
PR Newswire Europe - Tue Aug 04, 6:31AM CDT
AMRI today reported financial and operating results for the second quarter ended June 30, 2015.
AMRI: 22.20 (+0.19)
PerkinElmer Beats Q2 Earnings and Revenues; Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 8:57AM CDT
PerkinElmer Inc (PKI) reported second-quarter 2015 earnings of 60 cents per share, which surpassed the Zacks Consensus Estimate by a penny.
JNJ: 100.52 (+0.72), BRKR: 21.25 (+0.09), AMRI: 22.20 (+0.19), PKI: 52.85 (-0.07)
Albany Molecular Research Up 15.0% Since SmarTrend Uptrend Call (AMRI)
Comtex SmarTrend(R) - Thu Jul 30, 11:41AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on March 11th, 2015 at $18.03. In approximately 5 months, Albany Molecular Research has returned 14.95% as of today's recent price of $20.72.
AMRI: 22.20 (+0.19)
AMRI to Announce Second Quarter 2015 Results
PR Newswire - Tue Jul 21, 7:00AM CDT
AMRI (NASDAQ: AMRI) today announced it will issue second quarter 2015 financial results before the opening of the market on Tuesday, August 4, 2015. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 8:30 a.m. ET.
AMRI: 22.20 (+0.19)
Albany Molecular Research Has Returned 16.0% Since SmarTrend Recommendation (AMRI)
Comtex SmarTrend(R) - Thu Jul 16, 9:28AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on March 11th, 2015 at $18.03. In approximately 4 months, Albany Molecular Research has returned 16.01% as of today's recent price of $20.91.
AMRI: 22.20 (+0.19)
AMRI Acquires Gadea Pharmaceutical Group
PR Newswire Europe - Thu Jul 16, 6:30AM CDT
- Strategically expands AMRI's API portfolio through Crystal Pharma, positioning AMRI as a source of specialty and generic API
AMRI: 22.20 (+0.19)
Drug Discovery Outsourcing Market Forecast 2015-2025: Opportunities for Leading Companies
PR Newswire - Mon Jul 13, 6:24PM CDT
Report DetailsDrug discovery outsourcing - your guide to the commercial potential of services and companies in this marketWhere is the drug discovery outsourcing market heading? Visiongain's new report gives you revenue predictions for the drug discovery outsourcing market and its submarkets from 2015 to 2025, helping you stay ahead.Our new 223-page report provides 149 tables, charts, and graphs. Discover the growing trends of this industry. In particular, our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, drivers and restraints, and revenue predictions.Besides revenue forecast to 2025, this report provides you with market shares, business outlooks, qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial partnerships. Also, read the full transcript of three exclusive expert opinion interviews to inform you about prospects for investments and sales:- Dr. Mario Polywka, Chief Operating Officer, Evotec- Dr. John Davis, Director of Discovery & Dave Roberts, Business Development Director, Radiochemistry, Selcia- Dr. Paul Overton, Executive VP, Business Development & Marketing, ApuitSee revenue forecasts for leading drug discovery outsourcing sectorsAlong with prediction of overall world market value to 2025, our report shows you revenue forecasting for the four services sectors at world level:- Chemistry services market forecast 2015-2025- Biology services market forecast 2015-2025- Lead optimisation market forecast 2015-2025- Lead identification and screening market forecast 2015-2025The analysis helps you identify market potential with individual revenue forecasts, annual growth rates and CAGRs and market shares.Discover prospects of the leading national markets for the drug discovery outsourcingThe drug discovery outsourcing market is becoming increasingly global as companies look to lower costs by off-shoring their work to CROs based in emerging economies.You will discover individual revenue forecasts, annual growth rates, CAGRs, and market shares to 2025, as well as written supporting analyses for each of the 13 leading national markets and the rest of the world (RoW):- US- Japan- Germany- France- UK- Italy- Spain- China- Brazil- Russia- India- South Korea- Mexico- Rest of the WorldDemand for CROs based in emerging markets will be a major driver of growth in this market.Leading companies and potential for market growthOur new study predicts the world market for drug discovery outsourcing will reach $16.6bn in 2015. There is the increasing trend for pharmaceutical and biotech companies to form partnerships and alliances with CROs during the early drug discovery phase.Our research profiles leading companies, assessing their financial performance and products. You will see which organisations hold the greatest potential and what services each offer. See the profiles of 14 leading companies:- Albany Molecular Research (AMRI)- Aptuit- Charles River Laboratories (Acquired Galapagos CRO in 2014)- Covance (Acquired by LabCorp in 2015)- Cyprotex- Domainex- Evotec- GenScript- Pharmaceutical Product Development (PPD)- Quintiles- Selcia- Viva Biotech- WIL Research Laboratories- WuXi AppTecIn general, a company profile gives you the following information:- Drug discovery revenue forecast from 2015 to 2025- Historical and recent revenue figures- Description of services and products- Assessment of recent developments - mergers and acquisitions (M&A), collaborations, partnerships and alliancesDiscover capabilities, progress, and commercial prospects, helping you stay ahead.How the Drug Discovery Outsourcing Market Forecast 2015-2025: Opportunities for Leading Companies report deliversIn summary, our 223-page report gives you the following knowledge:- Revenue forecast to 2025 for the world drug discovery outsourcing market and 4 leading submarkets - Discover the industry's prospects, finding promising areas for investment and revenues.- Revenue forecasts to 2025 for the leading 13 national markets - US, Japan, Germany, France, UK, Italy, Spain, Brazil, Russia, China, India, South Korea, Mexico and the Rest of the World- Assessment of 14 leading companies - hear about collaborations, partnerships, contracts and alliances and predicted revenues to 2025- Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages.- View opinions from our survey, seeing interviews with leading drug discovery outsourcing experts.You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.Information found nowhere elseWith our study you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions.Visiongain's study is for everybody needing commercial analyses for the drug discovery outsourcing market and leading CROs that offer these services. You find data, trends and predictions. Please order our report now.
AMRI: 22.20 (+0.19)
BUYINS.NET: AMRI, TRIB, BABY, CP Expected To Be Up Before Next Earnings Releases
M2 - Fri Jul 10, 6:36AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and earnings reports. Albany Molecular Research Inc (NASDAQ:AMRI), Trinity Biotech PLC (NASDAQ:TRIB), NATUS MEDICAL, INCORPORATION (NASDAQ:BABY), Canadian Pacific Railway Ltd (NYSE:CP) are all expected to be Up Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com . The following stocks are expected to go Up Before earnings are released Tuesday:
BABY: 46.26 (+0.99), TRIB: 18.36 (+0.58), CP: 158.45 (-0.37), AMRI: 22.20 (+0.19)
Albany Molecular Research Shares Up 13.2% Since SmarTrend's Buy Recommendation (AMRI)
Comtex SmarTrend(R) - Wed Jul 01, 9:31AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on March 11th, 2015 at $18.03. In approximately 4 months, Albany Molecular Research has returned 13.18% as of today's recent price of $20.40.
AMRI: 22.20 (+0.19)
AMRI and PerkinElmer Announce Drug Discovery Collaboration as part of the Buffalo Medical Innovation and Commercialization Hub
PR Newswire Europe - Wed Jun 17, 6:00AM CDT
-- New AMRI Drug Discovery Center to Enable Translational Research Platforms
AMRI: 22.20 (+0.19)
Albany Molecular Research Up 8.8% Since SmarTrend Uptrend Call (AMRI)
Comtex SmarTrend(R) - Mon Jun 15, 9:42AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on March 11th, 2015 at $18.03. In approximately 3 months, Albany Molecular Research has returned 8.79% as of today's recent price of $19.61.
AMRI: 22.20 (+0.19)
9.9% Return Seen to Date on SmarTrend Albany Molecular Research Call (AMRI)
Comtex SmarTrend(R) - Fri Jun 05, 10:13AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on March 11th, 2015 at $18.03. In approximately 3 months, Albany Molecular Research has returned 9.90% as of today's recent price of $19.81.
AMRI: 22.20 (+0.19)
AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y.
PR Newswire Europe - Mon Jun 01, 6:01AM CDT
-- Collaboration to Provide Broad Industry Access to Next-Generation Drug Discovery Technologies for Enhanced Customer Success
AMRI: 22.20 (+0.19)
Albany Molecular Research Has Returned 9.3% Since SmarTrend Recommendation (AMRI)
Comtex SmarTrend(R) - Thu May 28, 5:16PM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on March 11th, 2015 at $18.03. In approximately 3 months, Albany Molecular Research has returned 9.35% as of today's recent price of $19.71.
AMRI: 22.20 (+0.19)
Albany Molecular Research posts 2Q profit
Automated Insights - Tue Aug 04, 7:42AM CDT
ALBANY, N.Y. (AP) _ Albany Molecular Research Inc. (AMRI) on Tuesday reported second-quarter profit of $2.3 million.
AMRI: 22.20 (+0.19)
AMRI Announces Second Quarter 2015 Results
PR Newswire Europe - Tue Aug 04, 6:31AM CDT
AMRI today reported financial and operating results for the second quarter ended June 30, 2015.
AMRI: 22.20 (+0.19)
PerkinElmer Beats Q2 Earnings and Revenues; Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 8:57AM CDT
PerkinElmer Inc (PKI) reported second-quarter 2015 earnings of 60 cents per share, which surpassed the Zacks Consensus Estimate by a penny.
JNJ: 100.52 (+0.72), BRKR: 21.25 (+0.09), AMRI: 22.20 (+0.19), PKI: 52.85 (-0.07)
Albany Molecular Research Up 15.0% Since SmarTrend Uptrend Call (AMRI)
Comtex SmarTrend(R) - Thu Jul 30, 11:41AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on March 11th, 2015 at $18.03. In approximately 5 months, Albany Molecular Research has returned 14.95% as of today's recent price of $20.72.
AMRI: 22.20 (+0.19)
AMRI to Announce Second Quarter 2015 Results
PR Newswire - Tue Jul 21, 7:00AM CDT
AMRI (NASDAQ: AMRI) today announced it will issue second quarter 2015 financial results before the opening of the market on Tuesday, August 4, 2015. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 8:30 a.m. ET.
AMRI: 22.20 (+0.19)
Albany Molecular Research Has Returned 16.0% Since SmarTrend Recommendation (AMRI)
Comtex SmarTrend(R) - Thu Jul 16, 9:28AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on March 11th, 2015 at $18.03. In approximately 4 months, Albany Molecular Research has returned 16.01% as of today's recent price of $20.91.
AMRI: 22.20 (+0.19)
AMRI Acquires Gadea Pharmaceutical Group
PR Newswire Europe - Thu Jul 16, 6:30AM CDT
- Strategically expands AMRI's API portfolio through Crystal Pharma, positioning AMRI as a source of specialty and generic API
AMRI: 22.20 (+0.19)
Drug Discovery Outsourcing Market Forecast 2015-2025: Opportunities for Leading Companies
PR Newswire - Mon Jul 13, 6:24PM CDT
Report DetailsDrug discovery outsourcing - your guide to the commercial potential of services and companies in this marketWhere is the drug discovery outsourcing market heading? Visiongain's new report gives you revenue predictions for the drug discovery outsourcing market and its submarkets from 2015 to 2025, helping you stay ahead.Our new 223-page report provides 149 tables, charts, and graphs. Discover the growing trends of this industry. In particular, our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, drivers and restraints, and revenue predictions.Besides revenue forecast to 2025, this report provides you with market shares, business outlooks, qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial partnerships. Also, read the full transcript of three exclusive expert opinion interviews to inform you about prospects for investments and sales:- Dr. Mario Polywka, Chief Operating Officer, Evotec- Dr. John Davis, Director of Discovery & Dave Roberts, Business Development Director, Radiochemistry, Selcia- Dr. Paul Overton, Executive VP, Business Development & Marketing, ApuitSee revenue forecasts for leading drug discovery outsourcing sectorsAlong with prediction of overall world market value to 2025, our report shows you revenue forecasting for the four services sectors at world level:- Chemistry services market forecast 2015-2025- Biology services market forecast 2015-2025- Lead optimisation market forecast 2015-2025- Lead identification and screening market forecast 2015-2025The analysis helps you identify market potential with individual revenue forecasts, annual growth rates and CAGRs and market shares.Discover prospects of the leading national markets for the drug discovery outsourcingThe drug discovery outsourcing market is becoming increasingly global as companies look to lower costs by off-shoring their work to CROs based in emerging economies.You will discover individual revenue forecasts, annual growth rates, CAGRs, and market shares to 2025, as well as written supporting analyses for each of the 13 leading national markets and the rest of the world (RoW):- US- Japan- Germany- France- UK- Italy- Spain- China- Brazil- Russia- India- South Korea- Mexico- Rest of the WorldDemand for CROs based in emerging markets will be a major driver of growth in this market.Leading companies and potential for market growthOur new study predicts the world market for drug discovery outsourcing will reach $16.6bn in 2015. There is the increasing trend for pharmaceutical and biotech companies to form partnerships and alliances with CROs during the early drug discovery phase.Our research profiles leading companies, assessing their financial performance and products. You will see which organisations hold the greatest potential and what services each offer. See the profiles of 14 leading companies:- Albany Molecular Research (AMRI)- Aptuit- Charles River Laboratories (Acquired Galapagos CRO in 2014)- Covance (Acquired by LabCorp in 2015)- Cyprotex- Domainex- Evotec- GenScript- Pharmaceutical Product Development (PPD)- Quintiles- Selcia- Viva Biotech- WIL Research Laboratories- WuXi AppTecIn general, a company profile gives you the following information:- Drug discovery revenue forecast from 2015 to 2025- Historical and recent revenue figures- Description of services and products- Assessment of recent developments - mergers and acquisitions (M&A), collaborations, partnerships and alliancesDiscover capabilities, progress, and commercial prospects, helping you stay ahead.How the Drug Discovery Outsourcing Market Forecast 2015-2025: Opportunities for Leading Companies report deliversIn summary, our 223-page report gives you the following knowledge:- Revenue forecast to 2025 for the world drug discovery outsourcing market and 4 leading submarkets - Discover the industry's prospects, finding promising areas for investment and revenues.- Revenue forecasts to 2025 for the leading 13 national markets - US, Japan, Germany, France, UK, Italy, Spain, Brazil, Russia, China, India, South Korea, Mexico and the Rest of the World- Assessment of 14 leading companies - hear about collaborations, partnerships, contracts and alliances and predicted revenues to 2025- Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages.- View opinions from our survey, seeing interviews with leading drug discovery outsourcing experts.You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.Information found nowhere elseWith our study you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions.Visiongain's study is for everybody needing commercial analyses for the drug discovery outsourcing market and leading CROs that offer these services. You find data, trends and predictions. Please order our report now.
AMRI: 22.20 (+0.19)
BUYINS.NET: AMRI, TRIB, BABY, CP Expected To Be Up Before Next Earnings Releases
M2 - Fri Jul 10, 6:36AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and earnings reports. Albany Molecular Research Inc (NASDAQ:AMRI), Trinity Biotech PLC (NASDAQ:TRIB), NATUS MEDICAL, INCORPORATION (NASDAQ:BABY), Canadian Pacific Railway Ltd (NYSE:CP) are all expected to be Up Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com . The following stocks are expected to go Up Before earnings are released Tuesday:
BABY: 46.26 (+0.99), TRIB: 18.36 (+0.58), CP: 158.45 (-0.37), AMRI: 22.20 (+0.19)
Albany Molecular Research Shares Up 13.2% Since SmarTrend's Buy Recommendation (AMRI)
Comtex SmarTrend(R) - Wed Jul 01, 9:31AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on March 11th, 2015 at $18.03. In approximately 4 months, Albany Molecular Research has returned 13.18% as of today's recent price of $20.40.
AMRI: 22.20 (+0.19)
AMRI and PerkinElmer Announce Drug Discovery Collaboration as part of the Buffalo Medical Innovation and Commercialization Hub
PR Newswire Europe - Wed Jun 17, 6:00AM CDT
-- New AMRI Drug Discovery Center to Enable Translational Research Platforms
AMRI: 22.20 (+0.19)
Albany Molecular Research Up 8.8% Since SmarTrend Uptrend Call (AMRI)
Comtex SmarTrend(R) - Mon Jun 15, 9:42AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on March 11th, 2015 at $18.03. In approximately 3 months, Albany Molecular Research has returned 8.79% as of today's recent price of $19.61.
AMRI: 22.20 (+0.19)
9.9% Return Seen to Date on SmarTrend Albany Molecular Research Call (AMRI)
Comtex SmarTrend(R) - Fri Jun 05, 10:13AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on March 11th, 2015 at $18.03. In approximately 3 months, Albany Molecular Research has returned 9.90% as of today's recent price of $19.81.
AMRI: 22.20 (+0.19)
AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y.
PR Newswire Europe - Mon Jun 01, 6:01AM CDT
-- Collaboration to Provide Broad Industry Access to Next-Generation Drug Discovery Technologies for Enhanced Customer Success
AMRI: 22.20 (+0.19)
Albany Molecular Research Has Returned 9.3% Since SmarTrend Recommendation (AMRI)
Comtex SmarTrend(R) - Thu May 28, 5:16PM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on March 11th, 2015 at $18.03. In approximately 3 months, Albany Molecular Research has returned 9.35% as of today's recent price of $19.71.
AMRI: 22.20 (+0.19)
